Evidence map›Paper›PMID 32031478›Full record

ArticlePharmaceutical development and technology2020

Improving solubility and oral bioavailability of a novel antimalarial prodrug: comparing spray-dried dispersions with self-emulsifying drug delivery systems.

Suresh Potharaju, Shravan Kumar Mutyam, Mingtao Liu, Carol Green, Lisa Frueh, Aaron Nilsen, Sovitj Pou, Rolf Winter, Michael K Riscoe, Gita Shankar

Open access · greenAbstract read
In one paragraph

Article in Pharmaceutical development and technology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
1.5field-weighted citation impact, top 20% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 23 citations in OpenAlex.

  1. Review
  2. Review
  3. Review
  4. Long-acting intramuscular injections of ELQ-331, an antimalarial agent.European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences · 2024
    Article
  5. Synthesis of Deuterated Endochin-Like Quinolones.Journal of labelled compounds & radiopharmaceuticals · 2024
    Article
  6. Article
  7. Article
  8. Review
  9. Article
  10. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 2 institutions in 1 country.

Suresh PotharajuBiosciences Division, Pharmaceutical Sciences Laboratories, SRI International, Menlo Park, CA, USA.
Shravan Kumar MutyamBiosciences Division, Pharmaceutical Sciences Laboratories, SRI International, Menlo Park, CA, USA.
Mingtao LiuBiosciences Division, Pharmaceutical Sciences Laboratories, SRI International, Menlo Park, CA, USA.
Carol GreenBiosciences Division, Pharmaceutical Sciences Laboratories, SRI International, Menlo Park, CA, USA.
Lisa FruehExperimental Chemotherapy Lab, VA Medical Center, Portland, OR, USA.
Aaron NilsenExperimental Chemotherapy Lab, VA Medical Center, Portland, OR, USA.
Sovitj PouExperimental Chemotherapy Lab, VA Medical Center, Portland, OR, USA.
Rolf WinterExperimental Chemotherapy Lab, VA Medical Center, Portland, OR, USA.
Michael K RiscoeExperimental Chemotherapy Lab, VA Medical Center, Portland, OR, USA.
Gita ShankarBiosciences Division, Pharmaceutical Sciences Laboratories, SRI International, Menlo Park, CA, USA.
Portland VA Medical Center · USSRI International · US

Funding

Optimizing ELQs for Treatment and Prevention of MalariaR01AI100569 · NIAID · OREGON HEALTH & SCIENCE UNIVERSITY · PI Michael Kevin RISCOE · 2014 to 2026
$8.0M
Development of a Sustained Release Injectable Formulation for Long-Term Delivery of ELQsR01AI141412 · NIAID · OREGON HEALTH & SCIENCE UNIVERSITY · PI RISCOE, MICHAEL KEVIN · 2019 to 2022
$3.2M
Optimizing ELQs for Treatment and Prevention of MalariaR56AI100569 · NIAID · OREGON HEALTH & SCIENCE UNIVERSITY · PI RISCOE, MICHAEL KEVIN · 2012 to 2012
$574k
Pharmachin Optimization and TestingI01BX003312 · VA · PORTLAND VA MEDICAL CENTER · PI RISCOE, MICHAEL KEVIN · 2016 to 2025
–
BLR&D Research Career Scientist Renewal Award ApplicationIK6BX004857 · VA · PORTLAND VA MEDICAL CENTER · PI Michael Kevin RISCOE · 2020 to 2026
–
BLRD VA I01 BX003312BLRD VA IK6 BX004857NIAID NIH HHS R01 AI100569NIAID NIH HHS R01 AI141412NIAID NIH HHS R56 AI100569
6 · The paper itself

Abstract

To improve the solubility and oral bioavailability of a novel antimalarial agent ELQ-331(a prodrug of ELQ-300), spray-dried dispersions (SDD) and a self-emulsifying drug delivery system (SEDDS) were developed. SDD were prepared with polyvinyl caprolactam-polyvinyl acetate-polyethylene glycol graft copolymer (Soluplus

Indexed as

Administration, OralAnimalsAntimalarialsBiological AvailabilityDrug CompoundingDrug Delivery SystemsDrug StabilityEmulsionsExcipientsMaleMolecular StructurePolyethylene GlycolsPolyvinylsProdrugsQuinolonesRats, Sprague-Dawley6-Chloro-7-methoxy-2-methyl-3-(4-(4-(trifluoromethoxy)phenoxy)phenyl)quinolin-4(1H)-oneAntimalarialsEmulsionsExcipientsPolyethylene Glycolspolyvinyl caprolactam-polyvinyl acetate-polyethylene glycol graft copolymerPolyvinylsProdrugsQuinolonesamorphous formAntimalarial drugsoral bioavailabilityself-emulsifying drug delivery systems (SEDDS)spray-dried dispersions (SDD)

Identifiers

PMID32031478
PMCPMC8120996
OpenAlexW3005109638

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.